<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694915</url>
  </required_header>
  <id_info>
    <org_study_id>CR-60/9150</org_study_id>
    <nct_id>NCT00694915</nct_id>
  </id_info>
  <brief_title>Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder</brief_title>
  <acronym>STCC</acronym>
  <official_title>Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Pharnmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Pharnmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine and compare the effect of this treatment on&#xD;
      recurrence rate and to assess the toxicity in both arms of patients with STCC. Other&#xD;
      objectives include determining the effects of this treatment on quality of life, and&#xD;
      comparing the effect of Mycobacterium w on time to tumor progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2008</start_date>
  <completion_date type="Actual">October 7, 2015</completion_date>
  <primary_completion_date type="Actual">March 31, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recording of any clinical adverse reactions at anytime during the study for assessment of safety</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence Rate-Evaluated after 3 months by doing sonography, cystoscopy, and cytology</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life- The measure of an individual's sense of well-being and ability to carry out various activities</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor progression -will be evaluated every 3 months for 15 months during the study period</measure>
    <time_frame>15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Mw</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycobacterium w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bacillus Calmette-Guerin (BCG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mycobacterium w</intervention_name>
    <description>Immunomodulator</description>
    <arm_group_label>Mw</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG (Bacillus Calmette-Guerin)</intervention_name>
    <description>Immunotherapeutic agent</description>
    <arm_group_label>BCG</arm_group_label>
    <other_name>Bacillus Calmette Guerin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent.&#xD;
&#xD;
          -  Patients with newly diagnosed superficial transitional cell carcinoma with completely&#xD;
             resected papillary tumors and high probability of recurrence risk i.e. stage T1 Grade&#xD;
             2, T1 Grade 3 &amp; CIS.&#xD;
&#xD;
        and Ta or T1 disease with an increased risk of recurrence defined as 2 tumors (primary and&#xD;
        recurrent or 2 recurrences) within 1 year, 3 or more within the last 6 months and/ or&#xD;
        carcinoma in situ on at least one random biopsy.&#xD;
&#xD;
          -  18 years or above&#xD;
&#xD;
          -  ECOG of 0-2 range&#xD;
&#xD;
          -  life expectancy is at least 24 weeks.&#xD;
&#xD;
          -  Absolute neutrophil count≥1,500/c.mm&#xD;
&#xD;
          -  platelet count≥100,000//c.mm&#xD;
&#xD;
          -  Hemoglobin ≥9.0g/dL&#xD;
&#xD;
               -  No patient who has eczema will be allowed to participate in this study.&#xD;
&#xD;
               -  Patients who are immuno-compromised will not be enrolled.&#xD;
&#xD;
               -  Patients with severe hepatic dysfunctions or with evidence of Cirrhosis will not&#xD;
                  be enrolled.&#xD;
&#xD;
               -  Patients with uncontrolled diabetes mellitus will not be enrolled in the study&#xD;
&#xD;
               -  No evidence of residual tumor in the cystoscopy done 6 weeks after the TUR&#xD;
&#xD;
        Note: The effects of Investigational product on the developing human fetus is at the&#xD;
        recommended therapeutic dose are unknown. For this reason and because other therapeutic&#xD;
        agents used in this trial are known to be teratogenic, women of child bearing potential and&#xD;
        men must agree to use adequate contraception (hormonal or barrier method of birth control;&#xD;
        abstinence) prior to study entry and for the duration of study participation. Should a&#xD;
        woman become pregnant or suspect she is pregnant while participating in this study, she&#xD;
        should inform her treating physician immediately.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had cytotoxic chemotherapy or radiotherapy prior to entering the&#xD;
             study.&#xD;
&#xD;
          -  No patient who has eczema should be allowed to participate in this study.&#xD;
&#xD;
          -  Patients who are immuno-compromised should not be enrolled.&#xD;
&#xD;
          -  Patients with severe hepatic dysfunctions or evidence of Cirrhosis should not be&#xD;
             enrolled.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to agents used in the study.&#xD;
&#xD;
          -  Pregnant women or nursing women are excluded from this study because agents used in&#xD;
             the study have potential for teratogenic or abortifacient effects. Because there is&#xD;
             known potential risk for adverse events in nursing infants secondary to treatment of&#xD;
             the mother with investigational agent, breastfeeding should be discontinued if the&#xD;
             mother is treated with investigational product.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study&#xD;
             reagent&#xD;
&#xD;
          -  Previous splenectomy&#xD;
&#xD;
          -  Clinically significant active infection&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahesh Desai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Muljibhai Patel Urological Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N K Mohanty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>V M Medical College &amp; Safdarjang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amillal Bhat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S P Medical College &amp; AG of Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sujata Patwardhan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seth G S Medical College &amp; K E M Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Mammen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian Medical College, Vellore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sushil Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Choithram Hospital and Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B. R. Srivastav, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jitendra Amlani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urocare Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anup Kundu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Post Graduate Medical Education &amp; Research, S. S. K. M. Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. K. Moorthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lourdes Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shrawan K. Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post Graduate Institute of Medical Education &amp; Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Purshottam K. Puri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indira Gandhi Medical College, Shimla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajeev Sood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Ram Manohar Lohia Hospital &amp; PGIMER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Padmaraj Hegde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasturba Medical College &amp; Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yathish Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.R.R. Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urocare Hospital</name>
      <address>
        <city>Rajkot</city>
        <state>Gujarat</state>
        <zip>360002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muljibhai Patel Urological Hospital</name>
      <address>
        <city>Nadiad</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indira Gandhi Medical College</name>
      <address>
        <city>Shimla</city>
        <state>Himachal Pradesh</state>
        <zip>171001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.R.R. Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560090</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical college and Hospital</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lourdes Hospital</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choithram Hospital and Research Centre</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital and Research Institute</name>
      <address>
        <city>Gwalior</city>
        <state>Madya Pradesh</state>
        <zip>474009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seth G S Medical College &amp; K E M Hospital</name>
      <address>
        <city>Parel</city>
        <state>Mumbai</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.B.M. Hospital &amp; A.G. of Hospitals</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPGMER, S.S.K.M. Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ram Manohar Lohia Hospital &amp; PGIMER</name>
      <address>
        <city>New Delhi</city>
        <zip>110001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V M Medical College &amp; Safdarjang Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STCC (Superficial Transitional Cell Carcinoma)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

